Share Price and Basic Stock Data
Last Updated: November 8, 2025, 5:39 am
| PEG Ratio | 9.64 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Alembic Pharmaceuticals Ltd operates in the pharmaceuticals sector with a current market capitalization of ₹17,801 Cr. The company reported sales of ₹6,229 Cr for the fiscal year ending March 2024, which rose to ₹6,672 Cr for the fiscal year ending March 2025. This marks a significant increase from ₹5,653 Cr in the previous fiscal year, indicating a robust growth trajectory. The quarterly sales figures also demonstrate a consistent upward trend, with the latest reported sales for June 2025 at ₹1,711 Cr, compared to ₹1,262 Cr in June 2022. Such growth is underpinned by strategic product launches and an expanding market presence. The company’s operating profit margin (OPM) stood at 15% for the fiscal year ending March 2025, reflecting operational efficiency despite rising costs. Overall, Alembic’s revenue growth aligns with the broader pharmaceutical industry trends in India, which is projected to grow at a CAGR of around 10% over the next few years, driven by increasing healthcare demands and a growing population.
Profitability and Efficiency Metrics
The profitability metrics of Alembic Pharmaceuticals reveal a mixed performance. The net profit for the fiscal year ending March 2025 was reported at ₹582 Cr, down from ₹616 Cr in the previous year. However, the earnings per share (EPS) for March 2025 stood at ₹29.68, reflecting a resilient earning capacity despite fluctuations in net profit. The return on equity (ROE) was recorded at 11.23%, while the return on capital employed (ROCE) was at 14.40%, indicating effective utilization of capital. The interest coverage ratio (ICR) remained strong at 13.34x, suggesting that the company can comfortably meet its interest obligations. The cash conversion cycle (CCC) has lengthened to 363 days, which could indicate potential liquidity challenges, although it remains within manageable levels. Overall, while Alembic’s profitability metrics are generally positive, the decline in net profit and an increasing CCC may warrant closer scrutiny by investors.
Balance Sheet Strength and Financial Ratios
Alembic Pharmaceuticals maintains a robust balance sheet with total assets reported at ₹7,773 Cr for the fiscal year ending March 2025. The company’s reserves stood at ₹5,152 Cr, providing a solid cushion against economic uncertainties. However, total borrowings increased to ₹1,258 Cr, a notable rise from ₹513 Cr the previous year, which may raise concerns regarding leverage. The debt-to-equity ratio is relatively low at 0.23, indicating prudent financial management. The company’s current ratio is reported at 1.69, suggesting good short-term financial health, while the quick ratio at 0.74 indicates potential liquidity constraints in meeting immediate liabilities. Alembic’s price-to-book value (P/BV) ratio is 3.52x, which is high compared to typical sector ranges, reflecting strong market expectations regarding future growth. The financial ratios indicate that while Alembic is financially sound, the rising debt levels may require monitoring in the context of its operational cash flows.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Alembic Pharmaceuticals reflects a stable and concentrated ownership structure, with promoters holding 69.74% of the equity. This level of promoter holding is indicative of strong management commitment, which can bolster investor confidence. Foreign institutional investors (FIIs) account for 4.04% of the shareholding, while domestic institutional investors (DIIs) hold 16.30%. The public shareholding stands at 9.92%, indicating a relatively low float, which can lead to higher volatility in the stock price. Over recent quarters, the number of shareholders has fluctuated, with 89,969 shareholders reported as of December 2024. The consistent promoter stake and increasing institutional investment suggest a growing interest in Alembic, although the low public shareholding could pose liquidity risks. Overall, the ownership structure is favorable for long-term investors, particularly given the promoters’ substantial stake.
Outlook, Risks, and Final Insight
Looking ahead, Alembic Pharmaceuticals faces a landscape filled with both opportunities and risks. Key strengths include a solid revenue growth trajectory, backed by a robust product pipeline and a strong balance sheet. However, challenges such as increasing debt levels and a rising cash conversion cycle could pose risks to liquidity and financial stability. The company’s ability to manage operational costs effectively while navigating regulatory challenges in the pharmaceutical sector will be crucial. Additionally, competition within the industry, particularly from generics, could pressure margins. Should Alembic successfully leverage its strengths while addressing these risks, it can enhance shareholder value significantly. Conversely, any missteps in managing debt or operational efficiency could hamper growth and investor sentiment. Overall, Alembic Pharmaceuticals remains a compelling player in the pharmaceuticals sector, but vigilance is warranted given the evolving market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Alembic Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.86 | 198.43 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,262 | 1,475 | 1,509 | 1,406 | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 |
| Expenses | 1,255 | 1,244 | 1,274 | 1,203 | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 |
| Operating Profit | 7 | 231 | 235 | 204 | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 |
| OPM % | 1% | 16% | 16% | 14% | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% |
| Other Income | 1 | 0 | 0 | 1 | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 |
| Interest | 9 | 12 | 15 | 14 | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 |
| Depreciation | 67 | 68 | 67 | 74 | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 |
| Profit before tax | -67 | 151 | 154 | 116 | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 |
| Tax % | -2% | 12% | 21% | -31% | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% |
| Net Profit | -66 | 133 | 122 | 153 | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 |
| EPS in Rs | -3.35 | 6.78 | 6.20 | 7.76 | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.80 | 7.04 | 7.98 | 7.85 |
Last Updated: August 20, 2025, 2:05 pm
Below is a detailed analysis of the quarterly data for Alembic Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,711.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,770.00 Cr. (Mar 2025) to 1,711.00 Cr., marking a decrease of 59.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,430.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,498.00 Cr. (Mar 2025) to 1,430.00 Cr., marking a decrease of 68.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 271.00 Cr. (Mar 2025) to 281.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Mar 2025) to 16.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 8.00 Cr..
- For Interest, as of Jun 2025, the value is 24.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 25.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 69.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 190.00 Cr.. The value appears to be declining and may need further review. It has decreased from 192.00 Cr. (Mar 2025) to 190.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Jun 2025, the value is 19.00%. The value appears to be increasing, which may not be favorable. It has increased from 18.00% (Mar 2025) to 19.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 157.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 3.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.85. The value appears to be declining and may need further review. It has decreased from 7.98 (Mar 2025) to 7.85, marking a decrease of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:20 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,863 | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 6,821 |
| Expenses | 1,506 | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,296 | 5,664 | 5,769 |
| Operating Profit | 358 | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,052 |
| OPM % | 19% | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 15% | 15% | 15% |
| Other Income | 4 | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | 61 |
| Interest | 10 | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 89 |
| Depreciation | 40 | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 283 |
| Profit before tax | 311 | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 740 |
| Tax % | 24% | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | 3% | 18% | |
| Net Profit | 236 | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 601 |
| EPS in Rs | 12.49 | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 | 30.67 |
| Dividend Payout % | 24% | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | 35% | 37% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 19.92% | 154.42% | -44.03% | 2.48% | 41.16% | 37.39% | 43.07% | -54.54% | -34.36% | 80.12% | -5.52% |
| Change in YoY Net Profit Growth (%) | 0.00% | 134.50% | -198.44% | 46.51% | 38.68% | -3.77% | 5.68% | -97.61% | 20.18% | 114.47% | -85.64% |
Alembic Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 8% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 14% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 10:45 pm
Balance Sheet
Last Updated: May 13, 2025, 3:55 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 638 | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 |
| Borrowings | 109 | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 513 | 1,258 |
| Other Liabilities | 432 | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,114 | 1,324 |
| Total Liabilities | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 |
| Fixed Assets | 397 | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 |
| CWIP | 21 | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 | 837 |
| Investments | 3 | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 |
| Other Assets | 796 | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,281 | 4,285 |
| Total Assets | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 |
Below is a detailed analysis of the balance sheet data for Alembic Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 39.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 39.00 Cr..
- For Reserves, as of Mar 2025, the value is 5,152.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,779.00 Cr. (Mar 2024) to 5,152.00 Cr., marking an increase of 373.00 Cr..
- For Borrowings, as of Mar 2025, the value is 1,258.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 513.00 Cr. (Mar 2024) to 1,258.00 Cr., marking an increase of 745.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1,324.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,114.00 Cr. (Mar 2024) to 1,324.00 Cr., marking an increase of 210.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 7,773.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,446.00 Cr. (Mar 2024) to 7,773.00 Cr., marking an increase of 1,327.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2,524.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,547.00 Cr. (Mar 2024) to 2,524.00 Cr., marking a decrease of 23.00 Cr..
- For CWIP, as of Mar 2025, the value is 837.00 Cr.. The value appears strong and on an upward trend. It has increased from 524.00 Cr. (Mar 2024) to 837.00 Cr., marking an increase of 313.00 Cr..
- For Investments, as of Mar 2025, the value is 127.00 Cr.. The value appears strong and on an upward trend. It has increased from 93.00 Cr. (Mar 2024) to 127.00 Cr., marking an increase of 34.00 Cr..
- For Other Assets, as of Mar 2025, the value is 4,285.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,281.00 Cr. (Mar 2024) to 4,285.00 Cr., marking an increase of 1,004.00 Cr..
- For Total Assets, as of Mar 2025, the value is 7,773.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,446.00 Cr. (Mar 2024) to 7,773.00 Cr., marking an increase of 1,327.00 Cr..
Notably, the Reserves (5,152.00 Cr.) exceed the Borrowings (1,258.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 249.00 | 139.00 | -113.00 | 526.00 | -65.00 | 873.00 | 0.00 | -583.00 | 157.00 | -40.00 | 419.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 64 | 40 | 40 | 61 | 45 | 69 | 24 | 56 | 68 | 60 | 77 |
| Inventory Days | 159 | 196 | 266 | 269 | 302 | 356 | 417 | 431 | 406 | 315 | 350 | 466 |
| Days Payable | 148 | 166 | 264 | 213 | 313 | 237 | 220 | 194 | 178 | 145 | 157 | 179 |
| Cash Conversion Cycle | 65 | 94 | 42 | 96 | 51 | 164 | 266 | 261 | 283 | 237 | 253 | 363 |
| Working Capital Days | 45 | 32 | 36 | 61 | 69 | 24 | 50 | 73 | 74 | 77 | 88 | 87 |
| ROCE % | 44% | 38% | 66% | 29% | 22% | 23% | 24% | 26% | 11% | 7% | 13% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Small Cap Fund - Regular Plan | 3,427,766 | 2.06 | 363.03 | 3,427,766 | 2025-04-22 17:25:43 | 0% |
| DSP Mid Cap Fund | 3,210,569 | 1.69 | 340.03 | 3,210,569 | 2025-04-22 15:57:00 | 0% |
| DSP Healthcare Fund | 1,423,563 | 5.14 | 150.77 | 1,423,563 | 2025-04-22 15:57:00 | 0% |
| DSP Small Cap Fund | 1,409,091 | 0.9 | 149.24 | 1,409,091 | 2025-04-22 15:57:00 | 0% |
| DSP ELSS Tax Saver Fund | 1,252,667 | 0.76 | 132.67 | 1,252,667 | 2025-04-22 17:25:43 | 0% |
| DSP Top 100 Equity Fund | 608,603 | 1.45 | 64.46 | 608,603 | 2025-04-22 15:57:00 | 0% |
| Aditya Birla Sun Life Small Cap Fund | 515,665 | 1.04 | 54.61 | 515,665 | 2025-04-22 17:25:43 | 0% |
| Edelweiss Mid Cap Fund | 350,586 | 0.5 | 37.13 | 350,586 | 2025-04-22 15:57:00 | 0% |
| Kotak India EQ Contra Fund - Regular Plan | 293,000 | 0.79 | 31.03 | 293,000 | 2025-04-22 15:57:00 | 0% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 240,291 | 2.95 | 25.45 | 240,291 | 2025-04-22 17:25:43 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 60.81 |
| Diluted EPS (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 60.81 |
| Cash EPS (Rs.) | 43.74 | 45.25 | 32.99 | 40.83 | 66.05 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 |
| Revenue From Operations / Share (Rs.) | 339.46 | 316.90 | 287.59 | 269.95 | 274.39 |
| PBDIT / Share (Rs.) | 53.46 | 48.93 | 36.18 | 47.04 | 79.75 |
| PBIT / Share (Rs.) | 39.29 | 35.05 | 22.17 | 32.45 | 70.42 |
| PBT / Share (Rs.) | 35.94 | 32.20 | 19.61 | 31.55 | 69.60 |
| Net Profit / Share (Rs.) | 29.57 | 31.38 | 18.97 | 26.23 | 56.72 |
| NP After MI And SOA / Share (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 59.94 |
| PBDIT Margin (%) | 15.74 | 15.43 | 12.58 | 17.42 | 29.06 |
| PBIT Margin (%) | 11.57 | 11.06 | 7.70 | 12.02 | 25.66 |
| PBT Margin (%) | 10.58 | 10.15 | 6.82 | 11.68 | 25.36 |
| Net Profit Margin (%) | 8.71 | 9.90 | 6.59 | 9.71 | 20.67 |
| NP After MI And SOA Margin (%) | 8.74 | 9.88 | 6.05 | 9.81 | 21.84 |
| Return on Networth / Equity (%) | 11.23 | 12.78 | 7.82 | 9.94 | 22.97 |
| Return on Capital Employeed (%) | 14.40 | 13.80 | 9.58 | 11.79 | 25.49 |
| Return On Assets (%) | 7.50 | 9.55 | 5.53 | 7.31 | 17.56 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Total Debt / Equity (X) | 0.23 | 0.08 | 0.14 | 0.12 | 0.03 |
| Asset Turnover Ratio (%) | 0.93 | 0.98 | 0.77 | 0.73 | 0.79 |
| Current Ratio (X) | 1.69 | 2.12 | 1.78 | 1.67 | 2.01 |
| Quick Ratio (X) | 0.74 | 0.98 | 0.87 | 0.72 | 0.85 |
| Inventory Turnover Ratio (X) | 0.85 | 0.89 | 0.86 | 0.78 | 0.93 |
| Dividend Payout Ratio (NP) (%) | 37.06 | 25.53 | 57.47 | 52.82 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 25.08 | 17.69 | 31.83 | 34.06 | 0.00 |
| Earning Retention Ratio (%) | 62.94 | 74.47 | 42.53 | 47.18 | 0.00 |
| Cash Earning Retention Ratio (%) | 74.92 | 82.31 | 68.17 | 65.94 | 0.00 |
| Interest Coverage Ratio (X) | 13.34 | 17.11 | 14.17 | 52.15 | 97.85 |
| Interest Coverage Ratio (Post Tax) (X) | 8.21 | 11.98 | 8.43 | 30.08 | 70.59 |
| Enterprise Value (Cr.) | 19368.46 | 19611.97 | 10301.50 | 15131.79 | 19003.45 |
| EV / Net Operating Revenue (X) | 2.90 | 3.15 | 1.82 | 2.85 | 3.52 |
| EV / EBITDA (X) | 18.43 | 20.39 | 14.49 | 16.37 | 12.12 |
| MarketCap / Net Operating Revenue (X) | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 |
| Retention Ratios (%) | 62.93 | 74.46 | 42.52 | 47.17 | 0.00 |
| Price / BV (X) | 3.52 | 4.01 | 2.23 | 2.78 | 3.70 |
| Price / Net Operating Revenue (X) | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 |
After reviewing the key financial ratios for Alembic Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
- For Diluted EPS (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
- For Cash EPS (Rs.), as of Mar 25, the value is 43.74. This value is within the healthy range. It has decreased from 45.25 (Mar 24) to 43.74, marking a decrease of 1.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.10. It has increased from 245.14 (Mar 24) to 264.10, marking an increase of 18.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.10. It has increased from 245.14 (Mar 24) to 264.10, marking an increase of 18.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 339.46. It has increased from 316.90 (Mar 24) to 339.46, marking an increase of 22.56.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.46. This value is within the healthy range. It has increased from 48.93 (Mar 24) to 53.46, marking an increase of 4.53.
- For PBIT / Share (Rs.), as of Mar 25, the value is 39.29. This value is within the healthy range. It has increased from 35.05 (Mar 24) to 39.29, marking an increase of 4.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 35.94. This value is within the healthy range. It has increased from 32.20 (Mar 24) to 35.94, marking an increase of 3.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 29.57. This value is within the healthy range. It has decreased from 31.38 (Mar 24) to 29.57, marking a decrease of 1.81.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.68. This value is within the healthy range. It has decreased from 31.33 (Mar 24) to 29.68, marking a decrease of 1.65.
- For PBDIT Margin (%), as of Mar 25, the value is 15.74. This value is within the healthy range. It has increased from 15.43 (Mar 24) to 15.74, marking an increase of 0.31.
- For PBIT Margin (%), as of Mar 25, the value is 11.57. This value is within the healthy range. It has increased from 11.06 (Mar 24) to 11.57, marking an increase of 0.51.
- For PBT Margin (%), as of Mar 25, the value is 10.58. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 10.58, marking an increase of 0.43.
- For Net Profit Margin (%), as of Mar 25, the value is 8.71. This value is within the healthy range. It has decreased from 9.90 (Mar 24) to 8.71, marking a decrease of 1.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.74. This value is within the healthy range. It has decreased from 9.88 (Mar 24) to 8.74, marking a decrease of 1.14.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.23. This value is below the healthy minimum of 15. It has decreased from 12.78 (Mar 24) to 11.23, marking a decrease of 1.55.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.40. This value is within the healthy range. It has increased from 13.80 (Mar 24) to 14.40, marking an increase of 0.60.
- For Return On Assets (%), as of Mar 25, the value is 7.50. This value is within the healthy range. It has decreased from 9.55 (Mar 24) to 7.50, marking a decrease of 2.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.23, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.93. It has decreased from 0.98 (Mar 24) to 0.93, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.69, marking a decrease of 0.43.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.74, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 4. It has decreased from 0.89 (Mar 24) to 0.85, marking a decrease of 0.04.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.06. This value is within the healthy range. It has increased from 25.53 (Mar 24) to 37.06, marking an increase of 11.53.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 25.08. This value is within the healthy range. It has increased from 17.69 (Mar 24) to 25.08, marking an increase of 7.39.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.94. This value is within the healthy range. It has decreased from 74.47 (Mar 24) to 62.94, marking a decrease of 11.53.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 74.92. This value exceeds the healthy maximum of 70. It has decreased from 82.31 (Mar 24) to 74.92, marking a decrease of 7.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.34. This value is within the healthy range. It has decreased from 17.11 (Mar 24) to 13.34, marking a decrease of 3.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.21. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 8.21, marking a decrease of 3.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 19,368.46. It has decreased from 19,611.97 (Mar 24) to 19,368.46, marking a decrease of 243.51.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.90. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.90, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 18.43. This value exceeds the healthy maximum of 15. It has decreased from 20.39 (Mar 24) to 18.43, marking a decrease of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 2.74, marking a decrease of 0.36.
- For Retention Ratios (%), as of Mar 25, the value is 62.93. This value is within the healthy range. It has decreased from 74.46 (Mar 24) to 62.93, marking a decrease of 11.53.
- For Price / BV (X), as of Mar 25, the value is 3.52. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 24) to 3.52, marking a decrease of 0.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 2.74, marking a decrease of 0.36.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alembic Pharmaceuticals Ltd:
- Net Profit Margin: 8.71%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.4% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.23% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.6 (Industry average Stock P/E: 55.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.23
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.71%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Alembic Road, Vadodra Gujarat 390003 | apl.investors@alembic.co.in http://www.alembicpharmaceuticals.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chirayu Amin | Chairman & CEO |
| Mr. Pranav Amin | Managing Director |
| Mr. Shaunak Amin | Managing Director |
| Mr. R K Baheti | Director - Finance & CFO |
| Mr. Jai Diwanji | Independent Director |
| Mr. Ashok Barat | Independent Director |
| Ms. Geeta Goradia | Independent Director |
| Mr. Manish Kejriwal | Independent Director |
FAQ
What is the intrinsic value of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd's intrinsic value (as of 08 November 2025) is 715.27 which is 22.42% lower the current market price of 922.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 18,122 Cr. market cap, FY2025-2026 high/low of 1,124/725, reserves of ₹5,152 Cr, and liabilities of 7,773 Cr.
What is the Market Cap of Alembic Pharmaceuticals Ltd?
The Market Cap of Alembic Pharmaceuticals Ltd is 18,122 Cr..
What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 08 November 2025?
The current stock price of Alembic Pharmaceuticals Ltd as on 08 November 2025 is 922.
What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alembic Pharmaceuticals Ltd stocks is 1,124/725.
What is the Stock P/E of Alembic Pharmaceuticals Ltd?
The Stock P/E of Alembic Pharmaceuticals Ltd is 28.6.
What is the Book Value of Alembic Pharmaceuticals Ltd?
The Book Value of Alembic Pharmaceuticals Ltd is 271.
What is the Dividend Yield of Alembic Pharmaceuticals Ltd?
The Dividend Yield of Alembic Pharmaceuticals Ltd is 1.19 %.
What is the ROCE of Alembic Pharmaceuticals Ltd?
The ROCE of Alembic Pharmaceuticals Ltd is 13.0 %.
What is the ROE of Alembic Pharmaceuticals Ltd?
The ROE of Alembic Pharmaceuticals Ltd is 11.4 %.
What is the Face Value of Alembic Pharmaceuticals Ltd?
The Face Value of Alembic Pharmaceuticals Ltd is 2.00.